Introduction
Mycobacterium tuberculosis (MTB) resistance to antimycobacterial drugs is a problem of immediate interest worldwide [1] . Experts generally agree that the prevalence of multi-drug resistant tuberculosis (MDR TB) has become uncontrolled all over the world; and some countries even consider MDR TB as a threat to national security [2, 3] . There is a growing number of strains that are resistant to one or more anti-TB drugs constituting the main cause for decreasing efficiency of chemotherapy, increasing number of patients with destructive forms, increasing frequency of significant residual post-tuberculosis alterations and increasing incidence of TB relapses. Therefore, an unfavorable epidemiological background for further spread of TB infection www.pneumonologia.viamedica.pl may occur [4, 5] . TB incidence associated with multi-drug resistance grows year by year [6] .
The real cause why some patients infected with MTB develop the disease accompanied by nonstable immunological response whilst the others demonstrate efficient immunogenic reaction intended to limit pathogen dissemination and prevent the disease remains unclear. Heredity impact on TB development was established in the studies of monozygotic and dizygotic twins. Thus, some evidence indicating that genetics may contribute into susceptibility to TB infection was obtained [7−9] .
Multifaceted interaction between pathogen and human immune system is a key factor influencing disease development and progression as well as the efficiency of applied treatment in patients with TB. Cytokines represent an important immunologic agents in MTB control. Three major cytokines involved in TB immunopathogenesis include IL-2, IL-4 and IL-10 [10−13] .
There is clear evidence that genetic peculiarities of a human being largely determine susceptibility to infection. Hence, a significant number of patients infected with MTB are apparently healthy subjects who developed an adequate projective immunity whereas only 5−10% of people have inefficient immunological response that may lead to TB development [14] .
Human susceptibility to MTB as an infectious antigen is encoded in various genes with different influence on pathologic phenotype development. Distribution of genotypes predisposed to higher risk of MTB infection and TB development or resistant to these factors is unique for every population and may be the reason for diverse immune response to infectious agent [15] .
Moreover, genetic regulation is a complex process of multiple genetic sites correlation [16] . Gene polymorphisms and protein products involved in immunologic protective response determine the degree of MTB resistance as well as disease severity and duration [17, 18] .
Th1-lymphocytes producing IL-2 play a protective role in TB immunopathogenesis, whereas Th2-lymphocytes producing IL-4 and IL-10 help to maintain function of Th1-lymphocytes. Th1/ Th2-lymphocytes are deemed not to be able to eliminate MTB from human body, probably due to inadequate cellular immune response. Consequently, humoral immune response occurs [10, 19−21] .
Considering functional role of IL-2, IL-4 and IL-10 as well as potential genetic variability of polymorphic variants, the study objective was to investigate whether IL-2, IL-4 and IL-10 gene polymorphisms are associated with MDR TB in Ukrainian population.
Material and methods
We observed 140 Caucasian patients with infiltrative pulmonary TB permanently residing in Kharkiv and Kharkiv region, Ukraine, aged between 20 and 70 years. The patients were assigned to two groups whether they suffer or do not suffer from pulmonary MDR TB: the first group -74 patients with MDR TB, the second group -66 patients not suffering from MDR TB (non-MDR TB). Patients were recruited at the Regional TB Hospital no 1 and Regional Anti-TB Dispensary no 1 both in Kharkiv; Regional Anti-TB Dispensary no 3 in Zmeev and Anti-Regional TB Dispensary no 4 in Izyum, both in Kharkiv region. All patients suffered from infiltrating pulmonary TB. All patients were HIV-negative.
The third control group included 30 apparently healthy subjects with comparable age characteristics, no positive history of pulmonary disease, no pathological findings in lungs according to chest X-ray examination, no chronic infectious disease, no acute allergic reactions and respiratory diseases for 3 months prior to the study.
Venous blood sampling was performed in the morning (between 8 and 9 a.m.) on the first days of hospitalization and following two months of patient's staying at hospital. Serum cytokine (IL-2, IL-10 and IL-4) levels were measured using standard ELISA kits.
Molecular methods: Genomic DNA was extracted from blood samples with the «DNA Express» (Liteh Company, Moscow, Russia), according to the manufacturer's instructions. The sets with primers were purchased from Liteh Company (Moscow, Russia) and used it according to the manufacturer's instructions. The method of investigation (for the sets real-time) -an allele-specific PCR using intercalating coloring SybrGreen. T330G -IL-2 rs2069762, C589T -IL-4 rs2243250 and G1082A -IL-10 rs1800896 were genotyped with amplification-refractory mutation system-polymerase chain reaction (ARMS-PCR).
Statistics packages MicrosoftExel and Statistica 7.0 were used for statistical analysis. Pearson's chi-square test with Yates' correction for continuity was used to determine if the data are normally distributed. Data received were analyzed using Student's t-test. The mean values were considered to be significantly different at p < 0.05. Data calculation was also performed using the relative risk (RR) with 95% probability interval estimation [22] . The project was approved by the Ethics Committee of the Kharkiv National Medical University, Ukraine. It was conducted according to the principles established in the Declaration of Helsinki. Every patient has signed written informed consent and has given his assent for DNA and blood tests as well as relevant clinical data collection.
Results
Statistically significant increase of serum IL-2 concentration was observed in patients with TB compared to the healthy subjects (p < 0.05). Serum IL-2 level significantly decreased in patients with pulmonary TB following two months of routine treatment compared to IL-2 level prior to treatment. Circulating IL-2 concentration was significantly increased in patients with pulmonary TB following two months of treatment in comparison with the healthy subjects ( Table 1) .
It was shown that homozygous (GG) and heterozygous (TG) genotypes of T330G polymorphism in the IL-2 gene are the most frequent in patients with pulmonary TB (c 2 = 34.60, p < 0.01). Homozygous (TT) genotype of the IL-2 gene was the less frequent genetic variant in TB patients. Homozygous (TT) genotype of the IL-2 gene was frequent in healthy subjects (p < 0.01) ( We observed statistically significant decreased serum levels of anti-inflammatory cytokines IL-4 and IL-10 compared with the healthy subjects at the point of treatment onset (p < 0.05). The IL-4 and IL-10 levels were significantly increased in patients with TB compared to the point of treatment onset. Although IL-10 concentrations significantly increased during the first two months of treatment in both TB groups, it was still lower in MDR TB group than that in the controls (Table 1) . Serum IL-4 and IL-10 levels were significantly lower in patients with MDR TB prior to chemotherapy and following two months of treatment compared with the non-MDR TB group.
The study revealed correlation between circulating inflammatory cytokines concentrations or level alterations and genotypes of polymorphisms in the IL-4 and IL-10 genes in the relevant groups of patients with pulmonary TB (Table 2 ). Our study of C589T and G1082A polymorphisms has shown the prevalence of mutational homozygous and heterozygous genotype polymorphisms of the IL-4 and IL-10 genes in patients with pulmonary TB (IL-4 -c 2 = 24.71 and IL-10 -c 2 = 34.14, p < 0.01). Polymorphisms of the IL-4 and IL-10 genes www.pneumonologia.viamedica.pl 
Discussion
It is well known that alterations in gene promoter region lead to modification of its transcriptional activity. T330G polymorphism located in the IL-2 promoter region should technically result in amino acid replacement in protein subunits corresponding to these polymorphic genes, in relation to origin of transcription and influence the level of gene expression and relevant protein level. Analysis of association between IL-2 secretion and allelic variant of T330G polymorphism in the IL-2 gene has shown that patients with TB have a statistically significant increase of serum IL-2 concentration compared to the third group. These changes may correspond to undifferentiated reaction of immune response to MTB elimination. It is well known that IL-2 has an impact on macrophages activation and direct cytotoxicity of T-cells, which accounts for protective role of IL-2 against tuberculosis [23] . On the contrary, it supports the activation of phagocytic elimination of MTB [24] .
Serum IL-2 level significantly decreased in patients with pulmonary TB following two months of routine treatment compared to IL-2 level prior to treatment. Circulating IL-2 concentration was significantly increased in patients with pulmonary TB following two months of treatment in comparison with the third group. Considering these changes, we can assume Th1-lymphocyte activity decrease in this group of patients. It may www.pneumonologia.viamedica.pl indicate a certain stabilization in patients with pulmonary TB taking into account the fact that serum IL-2 level is still significantly higher compared to healthy subjects.
Different genotypes of the IL-2 gene that we saw in our research may demonstrate genetic predisposition to the disease development. This hypothesis has been proved through analysis of association between polymorphisms and circulating cytokine levels in patients with pulmonary TB, which contributes to pathological changes in serum IL-2 levels in patients with TB on admission to hospital and following two months of chemotherapy.
Furthermore, we observed statistically significant decreased serum levels of anti-inflammatory cytokines IL-4 and IL-10 compared with the third group at the point of treatment onset. It indicates that Th2-lymphocyte activity was decreased prior to treatment. These changes may be associated with pronounced activation of Th1-lymphocytes during augmentation of immunity against tuberculosis in patients with pulmonary TB at the onset of chemotherapy. Changes of IL-4 and IL-10 conducted after two months of therapy, may be associated with the activation of Th2-lymphocytes and, as a result, a certain stabilization of Th1-lymphocytes. Evaluation of serum cytokine levels in patients following two months of anti-TB therapy and equivalent parameters in healthy subjects showed significant IL-4 level reduction in the first group, indicating relative insufficiency of IL-4 level restoration during the second month of treatment.
C589T polymorphism of the IL-4 gene and G1082A polymorphism of the IL-10 gene are deemed the most important for immunogenetic mechanisms of inflammation in TB patients [25, 26] . We conclude that homozygous genotype (CC) of the IL-4 gene and homozygous genotype (GG) of the IL-10 gene have a protective effect against infiltrative pulmonary TB.
Moreover, studied cytokine levels and polymorphisms may indicate an impact of polymorphisms on aforementioned interleukins production at the treatment onset and over a course of treatment that has been already shown in previous studies [27] . This finding was supported by significant changes of serum cytokines concentrations in patients with pulmonary TB on admission to hospital and following two months of chemotherapy.
Thus, heterozygous and mutational homozygous genotypes of the IL-2, IL-4 and IL-10 genes determining production level of studied interleukins represent an important risk factor of susceptibility to pulmonary TB development and disease progression into chronic phase. Heterozygous genotype activation of studied interleukin polymorphisms can contribute to MDR TB development through non-stabilized immune response of human body and resistant MTB strains infection prior to chemotherapy and over a course of treatment. Furthermore, it has not been demonstrated what mutations exactly are of crucial importance. We suppose that combination of genotypes but not separate genotypes of the genes plays a key role. The influence of genotypes combinations on susceptibility to infection and sustained bacterial infection is among the perspectives in IL-2, IL-4 and IL-10 immunogenetic studies.
Due to low numbers of study participants our results should be treated as preliminary.
Conclusions

Serum IL-2 level was significantly increased
in MDR TB patients compared to the group of patients not colonized by resistant MTB to anti-TB drugs at treatment onset and following two months of treatment. Circulating IL-4 and IL-10 levels were significantly increased in patients not suffering from MDR TB compared to the group of patients with resistant TB at treatment onset and following two months of antimycobacterial chemotherapy. T-330G polymorphism in the IL-2 gene were significantly the most frequent in the group of patients not suffering from resistant TB.
